Who can use Filspari(Sparsentan)?

Sparsentan is an oral dual endothelin-angiotensin receptor antagonist (DEARA) developed by Travere Therapeutics, Inc. in the United States.

Who can use Filspari(Sparsentan)?

The drug received accelerated approval from the U.S. Food and Drug Administration (FDA) in February 2023 and conditional marketing authorization from the European Union in April 2024.

FILSPARI is indicated to reduce proteinuria in adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease progression, typically with a urine protein-to-creatinine ratio (UPCR) of ≥1.5 g/g.

Related Columns

Sparsentan(Filspari)

Adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk...

WeChat Scan
Free Inquiry

What are the Indications of Sparsentan (Filspari)?

Sparsentan (Filspari) is a new type of oral medication, which was first approved for marketing in the United States in 2023. It is a dual endothelin and angiotensin II receptor antagonist, suitable fo...

What are the suitable populations for Sparsentan(Filspari)?

Sparsentan(Filspari) is a white or off-white oval film-coated tablet, is a unique single-molecule drug, used in clinical treatment of primary immunoglobulin A nephropathy (IgAN), has the title of...

What kinds of diseases is Sparsentan(Filspari) suitable for?

The main ingredient of Filspari is Sparsentan, which acts on ETAR and AT1R, can reduce the level of proteinuria in patients, and has the "orphan drug title" for the treatment of IgA nep...

Indications for Sparsentan

Sparsentan, also known as Filspari, is an innovative drug with specific therapeutic effects. This article will elaborate on the indications, drug interactions and basic pharmacological effects of Spar...